The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
|Articles|April 7, 2021
Rheumatoid Arthritis Quiz: Diabetes and Rheumatoid Arthritis
Author(s)Ingrid Torjesen
Many patients with rheumatoid arthritis (RA) also have diabetes mellitus, which can have an impact on their RA disease and its treatment. Test your knowledge of diabetes in RA with this quiz.
Advertisement
Is the following statement true or false?
Patients treated for type 2 diabetes have an increased risk of rheumatoid arthritis.
Advertisement
Related to this article
August 2026 rheumatology highlights include FDA approval of brepocitinib for dermatomyositis and garetosmab-grts for FOP, and new trial data.
In RA-BRIDGE and RA-BRANCH, baricitinib failed to demonstrate VTE noninferiority in patients with RA enriched for thromboembolic risk factors.
A Phase 2a basket trial produced ACR50 responses in 71% of refractory RA patients at 6 months.
Advertisement
Advertisement